Association between change in brain gray matter volume, cognition, and depression severity: Pre- and post- antidepressant pharmacotherapy for late-life depression.
Late-life depression (LLD) is associated with cognitive impairments and reduced gray matter volume (GMV); however the mechanisms underlying this association are not well understood. The goal of this study was to characterize changes in depression severity, cognitive function, and brain structure associated with pharmacologic antidepressant treatment for LLD. We administered a detailed neurocognitive battery and conducted structural magnetic resonance imaging (MRI) on 26 individuals with LLD, pre-/post-a 12-week treatment trial with venlafaxine. After calculating changes in cognitive performance, GMV, and depression severity, we calculated Pearson's correlations, performed permutation testing, and false discovery rate correction. We found that loss of GMV over 12 weeks in the superior orbital frontal gyrus was associated with less improvement in depression severity and that increased GMV in the same was associated with greater improvement in depression severity. We detected no associations between changes in cognitive performance and improvements in either depressive symptoms or changes in GMV.
['Droppa|K|K|', 'Karim|H T|HT|', 'Tudorascu|D L|DL|', 'Karp|J F|JF|', 'Reynolds|C F|CF|', 'Aizenstein|H J|HJ|', 'Butters|M A|MA|']
D000368:Aged D018687:Antidepressive Agents, Second-Generation D060825:Cognitive Dysfunction D003865:Depressive Disorder, Major D005260:Female D005500:Follow-Up Studies D066128:Gray Matter D006801:Humans D008279:Magnetic Resonance Imaging D008297:Male D008875:Middle Aged D017063:Outcome Assessment, Health Care D017397:Prefrontal Cortex D012720:Severity of Illness Index D000069470:Venlafaxine Hydrochloride
Cognition Late-life depression MRI